Posts by: Jose Marques Lopes, PhD

News

Adding isatuximab to a standard of care treatment of Pomalyst (pomalidomide) and low-dose dexamethasone prolonged the time without cancer progression in adults with relapsed or refractory multiple myeloma, according to ... Read more

January 30, 2019

clonoSEQ Assay Now Covered by Medicare for Multiple Myeloma and Acute Lymphoblastic Leukemia

News

The clonoSEQ Assay — a test that detects cancer cells present in very small numbers in a patient’s bone marrow — will now be covered by Medicare for patients with ... Read more

January 14, 2019

First Patient Treated with Phase 1 Trial Combo of Reolysin, Opdivo, and Kyprolis

News

A Phase 1 trial of the combination of Reolysin (pelareorep), Kyprolis (carfilzomib), and Opdivo (nivolumab) in relapsed multiple myeloma treated the first patient. The open-label, dose escalation study (NCT03605719) will ... Read more

January 7, 2019

Split Dosing Regimen of Darzalex Approved in Europe for Multiple Myeloma Patients

News

The European Commission has approved a new dosing regimen of the treatment Darzalex (daratumumab), allowing doctors to split the first infusion over two consecutive days, according to Janssen. The approval ... Read more

January 4, 2019

Aplidin Approved in Australia for Relapsed or Refractory Multiple Myeloma

News

Treatment with Aplidin (plitidepsin) in combination with dexamethasone was approved in Australia for multiple myeloma patients who have failed or are resistant to other therapies. The decision by the Therapeutic ... Read more

November 26, 2018

Excessive RNA Editing Linked to Myeloma Progression, Treatment Resistance, Study Suggests

News

Abnormally high production of an RNA editing enzyme called ADAR1 is associated with multiple myeloma progression and resistance to treatment, according to a study. The study, “Aberrant hyperediting of myeloma ... Read more

October 12, 2018

Combination of Reolysin, Opdivo, and Standard of Care to Be Tested in Phase 1 Trial for Multiple Myeloma

News

A combination of Oncolytics Biotech’s investigational therapy Reolysin (pelareorep) with anti-cancer medication Opdivo (nivolumab) and standard of care will be tested in patients with relapsed or refractory multiple myeloma. ... Read more

October 3, 2018

EMA Begins Review Process for Empliciti Triple Combo for Relapsed or Refractory Multiple Myeloma

News

The European Medicines Agency has validated Bristol-Myers Squibb’s application for Empliciti (elotuzumab), in combination with Pomalyst (pomalidomide) and low-dose dexamethasone, for the treatment of adults with multiple myeloma. Validation confirms that the ... Read more

September 12, 2018

Poseida’s Potential CAR T-cell Therapy Shows Positive Early Results in Phase 1 Multiple Myeloma Trial

News

Poseida Therapeutics’ CAR T-cell therapy candidate P-BCMA-101 is showing superior safety over alternatives and significant effectiveness in patients with relapsed or refractory multiple myeloma, according to early results of ... Read more

September 7, 2018

Combining Simple Blood Tests Might Accelerate Diagnosis of Myeloma

News

The combination of two blood tests routinely ordered by general practitioners could speed the diagnosis of myeloma, according to a new study. The research, “Early detection of multiple myeloma ... Read more

Posts by: Jose Marques Lopes, PhD

Jose Marques Lopes, PhD

Isatuximab Extends Time Without Cancer Progression in Phase 3 Trial of Multiple Myeloma

clonoSEQ Assay Now Covered by Medicare for Multiple Myeloma and Acute Lymphoblastic Leukemia

First Patient Treated with Phase 1 Trial Combo of Reolysin, Opdivo, and Kyprolis

Split Dosing Regimen of Darzalex Approved in Europe for Multiple Myeloma Patients

Aplidin Approved in Australia for Relapsed or Refractory Multiple Myeloma

Excessive RNA Editing Linked to Myeloma Progression, Treatment Resistance, Study Suggests

Combination of Reolysin, Opdivo, and Standard of Care to Be Tested in Phase 1 Trial for Multiple Myeloma

EMA Begins Review Process for Empliciti Triple Combo for Relapsed or Refractory Multiple Myeloma

Poseida’s Potential CAR T-cell Therapy Shows Positive Early Results in Phase 1 Multiple Myeloma Trial

Combining Simple Blood Tests Might Accelerate Diagnosis of Myeloma

Pin It on Pinterest